Genome Therapeutics Sees Drop in Q4 Earnings and R&D Spending, Net Losses Widen | GenomeWeb

NEW YORK, March 4 - Genome Therapeutics reported today a fall-off in revenues for the fourth quarter ended December 31, 2002, along with lower R&D spending and a slightly increased net loss.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.